By
Meredith Mazzotta
Published: March 9, 2012, 10:52 a.m.·
Tags:
None
Treating patients co-infected with HIV and tuberculosis (TB) can be tricky – as rifampin, a key sterilizing drug in TB regimens – can reduce concentrations of antiretrovirals administered at the same time, as well as other drug-drug complications. Early efforts to combat this phenomenon have unearthed a potential treatment candidate – an increased dose of dolutegravir (DTG), an investigational HIV integrase inhibitor currently in Phase III trials.
Read More →